Plain-English translation of NCT04590326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called , which works by targeting a protein found on certain cancer cells and activating your immune system to fight the cancer. You would receive this medication either by itself or combined with other immunotherapy drugs (, fianlimab, and/or ). The goal is to learn whether the medication is safe, what side effects it causes, and whether it can help shrink ovarian or uterine cancers.
Advanced ovarian and endometrial cancers are difficult to treat, especially after standard chemotherapy stops working. This medication is designed to work differently by targeting a specific protein on cancer cells and boosting your immune system's ability to recognize and destroy cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through injections or infusions at clinic visits, either alone or combined with other study drugs depending on which group you're assigned to. The study has two phases: first, researchers find the safest dose (where some participants may receive lower doses), and then expansion groups receive the established dose. You would have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and to track any side effects.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States